8-K: Cryoport Reports Mixed Q3 Results: Services Revenue Up, Product Sales Lag

Cryoport's Q3 2024 results show a 9% increase in Life Sciences Services revenue, but a 14% decrease in Life Sciences Products revenue, with the company reaffirming its full-year revenue guidance.

Summary

• Cryoport announced its financial results for the third quarter of 2024, showing a mixed performance.
• Life Sciences Services revenue increased by 9% year-over-year to $39.3 million, driven by a 12% increase in BioStorage/BioServices revenue.
• However, Life Sciences Products revenue decreased by 14% year-over-year to $17.4 million.
• Total revenue for the quarter was $56.7 million, a 1% increase compared to the same period last year.
• The company reaffirmed its full-year 2024 revenue guidance of $225 million to $235 million.
• Gross margin for services improved to 46%, while product gross margin decreased to 42.1%.
• The company reported a net income of $0.8 million for the quarter, compared to a net loss of $13.3 million in Q3 2023, primarily due to gains on debt extinguishment.
• Adjusted EBITDA was a negative $2.4 million for the quarter, an improvement from a negative $3.1 million in Q3 2023.
• Cryoport supported a record 691 global clinical trials as of September 30, 2024, with 79 trials in Phase 3.
• The company repurchased $175 million of its convertible senior notes for $154.5 million during the quarter.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive due to the growth in services revenue and improved profitability, but tempered by the decline in product sales and ongoing challenges. The reaffirmation of guidance and debt repurchase are positive signals.

Positives

• The Life Sciences Services segment showed strong growth, with a 9% increase in revenue.
• BioStorage/BioServices revenue grew by 12%, indicating strong demand for these services.
• Gross margin for Life Sciences Services improved to 46%, showing increased profitability in this segment.
• The company achieved a net income of $0.8 million for the quarter, a significant turnaround from the previous year's loss.
• Adjusted EBITDA improved year-over-year, moving closer to profitability.
• Cryoport successfully repurchased a substantial amount of its convertible senior notes, reducing debt.
• The company is on track to complete its cost reduction and capital realignment strategies by the end of the year.
• The number of supported clinical trials increased to 691, indicating strong market presence and growth potential.

Negatives

• Life Sciences Products revenue decreased by 14% year-over-year, indicating weakness in this segment.
• Total revenue growth was only 1% year-over-year, primarily due to the decline in product sales.
• Gross margin for Life Sciences Products decreased to 42.1%, impacting overall profitability.
• The company reported a net loss of $96.1 million for the first nine months of 2024, primarily due to an impairment loss.
• Adjusted EBITDA remained negative for the quarter, although improved year-over-year.
• Operating costs and expenses increased for the nine-month period, impacting overall profitability.

Risks

• The company acknowledges ongoing softness in product sales, which could continue to impact revenue.
• Macroeconomic and sector-specific challenges are expected to persist, potentially affecting the company's performance.
• The company's 2024 guidance is dependent on various factors outside of its control, such as economic conditions and supply chain issues.
• There are risks associated with completing the planned cost reduction and capital realignment measures.
• The company's business could be affected by various factors discussed in its SEC filings, including market acceptance and technical development risks.

Future Outlook

The company reaffirms its full-year 2024 revenue guidance of $225 million to $235 million and anticipates a return to positive adjusted EBITDA during 2025. They expect continued growth in their services business while acknowledging ongoing softness in product sales. They also anticipate up to four additional application filings and two new therapy approvals for the remainder of 2024, with two more possible approvals in January 2025.

Management Comments

• Jerrell Shelton, CEO of Cryoport, stated that the Life Sciences Services business showed 9% growth during the third quarter.
• Mr. Shelton noted a substantial improvement in gross margin to 46% for the services business.
• Mr. Shelton mentioned that the company is maintaining its full-year revenue forecast of $225 million to $235 million.
• Mr. Shelton highlighted the company's active execution of cost reduction and capital realignment strategies.
• Mr. Shelton believes that these measures will lead to a return to positive adjusted EBITDA during 2025.
• Mr. Shelton stated that the company is strategically positioned to leverage the anticipated long-term growth in the Life Sciences and the Cell & Gene Therapy market.

Industry Context

Cryoport's results reflect broader trends in the life sciences industry, where services are generally performing better than product sales. The company's focus on cell and gene therapy aligns with the growing demand in this sector. The launch of their IntegriCell Cryopreservation Solution also indicates a move towards addressing critical supply chain needs in the cell-based therapy market.

Comparison to Industry Standards

• Cryoport's 9% growth in Life Sciences Services is a positive sign, as many companies in the life sciences sector are experiencing slower growth or declines in product sales.
• The 12% growth in BioStorage/BioServices revenue is particularly strong, indicating a competitive advantage in this niche market.
• The improvement in gross margin for services to 46% is a positive trend, suggesting better cost management and pricing strategies.
• However, the 14% decline in product revenue is a concern, as it lags behind the performance of some competitors in the broader life sciences product market.
• Companies like Thermo Fisher Scientific and Danaher, which have a more diversified product portfolio, may not be experiencing the same level of product revenue decline.
• Cryoport's focus on cell and gene therapy is a strategic move, as this market is expected to grow significantly in the coming years, potentially outperforming other areas of the life sciences industry.
• The company's adjusted EBITDA is still negative, which is a concern compared to more established and profitable companies in the sector, but the improvement is a positive sign.

Stakeholder Impact

• Shareholders may view the improved net income and adjusted EBITDA positively, but the decline in product sales may cause concern.
• Employees may be affected by the ongoing cost reduction and capital realignment strategies.
• Customers will likely benefit from the company's continued focus on improving its services and expanding its capabilities.
• Suppliers may be impacted by the company's cost reduction efforts.
• Creditors may view the debt repurchase program positively, as it reduces the company's financial risk.

Next Steps

• The company plans to complete its cost reduction and capital realignment strategies by the end of the year.
• Cryoport anticipates up to four additional application filings and two new therapy approvals for the remainder of 2024.
• The company expects two possible approvals of new therapies in January of 2025.
• Cryoport will host a conference call on November 7, 2024, to discuss the results.

Key Dates

Keywords

Cryoport, Life Sciences, Supply Chain, Cell & Gene Therapy, BioLogistics, BioStorage, Clinical Trials, Revenue, EBITDA, Gross Margin, Financial Results